Who Generates Higher Gross Profit? Biogen Inc. or Incyte Corporation

Biogen leads, but Incyte's growth is impressive!

__timestamp	Biogen Inc.	Incyte Corporation
Wednesday, January 1, 2014	8532288000	508491000
Thursday, January 1, 2015	9523400000	726779000
Friday, January 1, 2016	9970100000	1047532000
Sunday, January 1, 2017	10643900000	1456737000
Monday, January 1, 2018	11636600000	1787760000
Tuesday, January 1, 2019	12422500000	2044510000
Wednesday, January 1, 2020	11639400000	2535374000
Friday, January 1, 2021	8872000000	2835276000
Saturday, January 1, 2022	7895100000	3187638000
Sunday, January 1, 2023	7302200000	3440649000
Monday, January 1, 2024	9675900000	3929149000

Unleashing insights

Biogen Inc. vs. Incyte Corporation: A Decade of Gross Profit Trends

In the competitive landscape of biotechnology, understanding which companies lead in profitability is crucial. Over the past decade, Biogen Inc. has consistently outperformed Incyte Corporation in terms of gross profit. From 2014 to 2023, Biogen's gross profit peaked in 2019, reaching nearly 12.4 billion, while Incyte's highest was in 2023, with approximately 3.4 billion. Despite Biogen's dominance, Incyte has shown remarkable growth, with its gross profit increasing by over 575% from 2014 to 2023. This trend highlights Incyte's rapid expansion and potential to challenge industry giants. As the biotech sector evolves, these financial insights provide a glimpse into the strategic maneuvers of these companies, offering investors and analysts a deeper understanding of their market positions.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025